Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Atrium Therapeutics earns $15M from Bristol Myers Squibb By Investing.com
Atrium Therapeutics received a $15 million development milestone payment from Bristol Myers Squibb for delivering a development candidate for an RNA-based therapy targeting a cardiology indication. This payment is part of a global licensing and research agreement that could see Atrium receive up to $1.35 billion in R&D milestone payments, $825 million in commercial milestone payments, and tiered royalties. Bristol Myers Squibb will fund all future clinical development, regulatory, and commercialization activities under the collaboration, which focuses on RNA-based therapies for cardiovascular conditions.